Every 8-K that RADNOSTIX INC (INIS) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow INIS and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full INIS filings page.
Radnostix Inc. (INIS), together with its wholly owned subsidiary International Isotopes Fluorine Products, agreed to sell assets associated with a depleted uranium deconversion and fluorine extraction project to HALEU Energy Fuel, a wholly owned subsidiary of NANO Nuclear Energy. At closing, the buyer parties are to pay the sellers $9.5 million in cash, less the Escrowed Funds and amounts paid to release liens, and issue Radnostix $4 million of restricted NANO common stock. The previously deposited $0.5 million in Escrowed Funds is to be released to Radnostix upon signing. The share count will be based on the common stock’s volume-weighted average price over the period specified in the agreement.
The assets include an NRC license, related intellectual property and technical materials, equipment, and project records; the contemplated facility was not constructed. The buyer will assume only certain liabilities arising under the purchased assets after closing, while other seller liabilities remain with the sellers. Closing is subject to NRC consent to the license transfer, other approvals, satisfactory site arrangements, and other conditions. The parties currently expect closing in approximately 90 to 120 days.
After closing, Radnostix intends to use net proceeds to support growth across its four radioisotope technology product segments through research and development and organic and inorganic initiatives.
Radnostix Inc. held its 2026 Annual Meeting of Shareholders on July 16, 2026 in Idaho Falls, Idaho. Stockholders approved the Radnostix Inc. 2026 Incentive Plan, which replaces the expired 2015 equity incentive plan and authorizes the issuance of up to 12,000,000 shares of common stock to employees, officers, directors and other service providers of Radnostix and its affiliates.
There were 309,307,669 shares of common stock represented in person or by proxy, approximately 58.46% of outstanding shares, constituting a quorum. All five director nominees were elected; for example, Robert Atcher received 235,894,311 votes for and 157,335 withheld, with 73,256,023 broker non-votes in the director elections. Two additional shareholder proposals were approved, including one that received 308,264,375 votes for, 353,856 against and 689,438 abstentions, and another with 232,417,556 for, 3,194,021 against, 440,069 abstentions and 73,256,023 broker non-votes.
Radnostix, Inc. entered an Asset Purchase Agreement to buy the Lara System technology platform and Ellexa Explorer software from Lucerno Dynamics. The initial purchase price is $900,000, split between $150,000 in cash and $750,000 in common stock valued using a 20‑day VWAP. The seller may receive up to an additional $750,000 in stock through regulatory and sales milestone payments, plus cash earn outs tied to future system sales.
The company also issued a $500,000 related party Convertible Promissory Note to Kershner Grosso & Co. maturing in 2031, bearing 5% annual interest and convertible into common stock at $0.07 per share, with a company call feature if the stock trades above $0.12 VWAP for 30 days. Radnostix amended several historic notes to remove liens on company assets, add similar conversion and forced‑conversion terms, and extend their maturities to March 31, 2031.
Radnostix Inc. has amended the terms of its Series C Convertible Redeemable Preferred Stock after approval by a majority of the Series C holders. The change extends the security’s maturity date by one year, moving it to February 28, 2028, while all other terms remain the same.
To implement this change, the company filed a Certificate of Amendment to the Statement of Designation for the Series C preferred stock with the Texas Secretary of State. The amendment formalizes the new maturity date without altering dividend, conversion, or other stated rights.
Radnostix, Inc. terminated its Asset Purchase Agreement with American Fuel Resources for the sale of its depleted uranium deconversion and fluorine extraction plant. The decision followed AFR’s request for a one-year extension after it could not pay the remaining $12,450,000 purchase price by the March 31, 2026 outside date.
AFR had previously made a non‑refundable $50,000 prepayment and twelve non‑refundable NRC extension fee payments totaling $120,000. With termination, Radnostix retains ownership of the DUF6 plant, which it believes has appreciated in value, and plans to evaluate future options for these assets.
The company also initiated a voluntary recall of specific lots of its Dibasic Sodium Phosphate Capsules shipped between August 19, 2024 and February 17, 2026. It expects a one‑time charge of about $75,000 in fourth‑quarter 2025 for inventory write‑offs and about $50,000 in first‑quarter 2026 for customer refunds, plus roughly $75,000 for new capsule inventory and an estimated $25,000 to $75,000 per week in lost revenue, which it believes will not extend beyond the second quarter.
International Isotopes Inc. reported that it has changed its corporate name to Radnostix, Inc. by filing a Certificate of Amendment in Texas on December 23, 2025. The board approved the change on October 21, 2025, and a majority of shareholders approved it by written consent on November 25, 2025.
The company explains that its business has expanded from radiochemicals and non-medical radioisotopes with an energy focus to a broader portfolio of radioisotope, theranostic, and related healthcare products and devices. Management believes the Radnostix, Inc. name better reflects this healthcare-focused direction. The common stock will continue to trade under the ticker "INIS" on the OTCQB, and shareholders do not need to take any action regarding existing stock certificates.
International Isotopes Inc. (INIS) approved a new employment agreement for CEO and President Shahe Bagerdjian. The term runs from July 18, 2025 to July 18, 2030, with an initial base salary of $314,000 and automatic 5% annual increases. He may receive additional $50,000 salary increases as quarterly revenue reaches $3.75M, $6.25M, $12.5M, $18.75M, and $25M, excluding one-time other income items.
The agreement grants 37,500,000 RSUs, vesting after the share price is at or above $0.10 (2.5M), $0.15 (5.0M), $0.20 (7.5M), $0.25 (10.0M), and $0.30 (12.5M) for 60 consecutive days and subject to a tax‑withholding cash condition or six months after the trigger date. Unvested RSUs accelerate upon termination without cause or immediately before a change of control while in good standing. He remains eligible for annual cash bonuses set by the Board.
Governance updates: Dr. Duke W. Fu was appointed an independent director and to the audit committee; he will receive 250,000 RSUs per annual term (vesting commencement July 11, 2026). The Board amended bylaws to limit special-meeting business to noticed items, add advance notice for business and director nominations, permit advisory directors, allow shareholder action by less than unanimous written consent, and add indemnification and insurance provisions.
International Isotopes Inc. (INIS) updated leadership agreements and corporate governance. The company entered a new employment agreement with CEO and President Shahe Bagerdjian, effective July 18, 2025, through July 18, 2030, with automatic one-year renewals. His initial annual base salary is $314,000 with automatic 5% yearly increases and potential $50,000 step-ups tied to quarterly revenue milestones at $3.75M, $6.25M, $12.5M, $18.75M, and $25M.
Bagerdjian received 37,500,000 RSUs vesting upon sustained share-price hurdles of $0.10, $0.15, $0.20, $0.25, and $0.30 and specified cash/withholding conditions; unvested RSUs vest upon termination without cause or immediately prior to a change of control if in good standing. A prior 6,500,000 RSU grant remains, with 3,000,000 vesting on April 17, 2026.
The Board appointed Dr. Duke W. Fu as an independent director and audit committee member; compensation includes 250,000 RSUs per annual term starting July 11, 2026. Amended bylaws add advance notice procedures for business and director nominations, clarify special meeting scope and scheduling, permit advisory directors, allow shareholder action by less than unanimous written consent, and add indemnification and insurance provisions.